https://www.biopharmadive.com/news/biomarin-roctavian-limit-sales-us-germany-italy-hemophilia/723402/
BioMarin pares Roctavian spending as it narrows sales focus | BioPharma Dive
The company plans to limit sales of the hemophilia gene therapy to the U.S., Italy and Germany, while ending most clinical development work.
biopharma divebiomarinparesroctavianspending
https://www.clinicaltrialsarena.com/analyst-comment/biomarins-roctavian-first-gene-therapy-hemophilia-a/
BioMarin Roctavian could be first gene therapy approved for Hemophilia A
Mar 23, 2022 - BioMarin's GENEr8-1 Phase III one-year results could see Roctavian become the first gene therapy available to hemophiliacs.
be firstgene therapybiomarinroctaviancould